Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation. Morgensztern D, Govindan R. J Thorac Oncol 2021;16:1999-2001.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Morgensztern D, Govindan R. Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation. J Thorac Oncol 2021;16:1999-2001.
PMID: 34809804